Clinical Trial Update: Daylight-PDT for AKs: Comparing Two Photosensitizers (BF-200 ALA and MAL) [Phase 4]

View source ↗

Summary

Phase 4 clinical trial comparing daylight photodynamic therapy using BF-200 ALA versus methyl aminolevulinate for actinic keratosis; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Actinic Keratosis

Drugs mentioned

• BF-200 ALA (5-aminolevulinic acid (ALA) topical photosensitizer)
• MAL (methyl aminolevulinate) (methyl aminolevulinate)

Snippet

Sponsor: Joint Authority for Päijät-Häme Social and Health Care | Conditions: Multiple Actinic Keratoses | Phase 4 | Status: COMPLETED | Results posted: 2016-07-11